Kite turns out to be a concerning investment for Gilead When Gilead acquired Kite for $12 billion (!), it was the talk of the industry for many months. It was a sign that Gilead was investing big in CAR-T cell therapy. Things have soured since, with Gilead cutting forecasts for drugs in the Kite pipeline. […]

Zolgensma sales grows Novartis’ gene therapy for spinal muscular dystrophy, Zolgensma has a $2.1 Million price tag. That has not stopped it from having an impressive growth interns of revenue. With more regulatory approvals in the pipeline, this trend only appears to continue upward. I know I only choose to write about Immunology and Oncology […]